Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.

Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA.

EMBO J. 2003 Dec 1;22(23):6267-76.

2.

Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.

ten Dijke P, Krause C, de Gorter DJ, Löwik CW, van Bezooijen RL.

J Bone Joint Surg Am. 2008 Feb;90 Suppl 1:31-5. doi: 10.2106/JBJS.G.01183. Review.

PMID:
18292354
3.

Bone morphogenetic proteins and their antagonists: the sclerostin paradigm.

van Bezooijen RL, Papapoulos SE, Löwik CW.

J Endocrinol Invest. 2005;28(8 Suppl):15-7. Review.

PMID:
16323824
4.

Identification of the disease-causing gene in sclerosteosis--discovery of a novel bone anabolic target?

Balemans W, Van Hul W.

J Musculoskelet Neuronal Interact. 2004 Jun;4(2):139-42. Review.

5.

SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.

van Bezooijen RL, ten Dijke P, Papapoulos SE, Löwik CW.

Cytokine Growth Factor Rev. 2005 Jun;16(3):319-27. Review.

PMID:
15869900
6.

The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis.

Yavropoulou MP, Xygonakis C, Lolou M, Karadimou F, Yovos JG.

Hormones (Athens). 2014 Oct-Dec;13(4):323-37. doi: 10.14310/horm.2002.1552. Review.

7.

Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles?

Sapir-Koren R, Livshits G.

Osteoporos Int. 2014 Dec;25(12):2685-700. doi: 10.1007/s00198-014-2808-0. Epub 2014 Jul 17. Review.

PMID:
25030653
8.

Sclerostin: a novel target for intervention in the treatment of osteoporosis.

Lewiecki EM.

Discov Med. 2011 Oct;12(65):263-73. Review.

9.

Osteocytes and WNT: the mechanical control of bone formation.

Galli C, Passeri G, Macaluso GM.

J Dent Res. 2010 Apr;89(4):331-43. doi: 10.1177/0022034510363963. Epub 2010 Mar 3. Review.

PMID:
20200416
10.

Does osteocytic SOST suppression mediate PTH bone anabolism?

Kramer I, Keller H, Leupin O, Kneissel M.

Trends Endocrinol Metab. 2010 Apr;21(4):237-44. doi: 10.1016/j.tem.2009.12.002. Epub 2010 Jan 13. Review.

PMID:
20074973
11.

The role of BMPs in bone anabolism and their potential targets SOST and DKK1.

Kamiya N.

Curr Mol Pharmacol. 2012 Jun;5(2):153-63. Review.

PMID:
21787290
12.

Sclerostin: current knowledge and future perspectives.

Moester MJ, Papapoulos SE, Löwik CW, van Bezooijen RL.

Calcif Tissue Int. 2010 Aug;87(2):99-107. doi: 10.1007/s00223-010-9372-1. Epub 2010 May 15. Review.

13.

Sclerostin and skeletal health.

Sharifi M, Ereifej L, Lewiecki EM.

Rev Endocr Metab Disord. 2015 Jun;16(2):149-56. doi: 10.1007/s11154-015-9311-6. Review.

PMID:
25669441
14.

[Bone and Nutrition. Sclerostin and bone metabolism].

Tatsumi S, Nagamoto K, Ogata M, Miyamoto K.

Clin Calcium. 2015 Jul;25(7):1043-7. doi: CliCa150710431047. Review. Japanese.

PMID:
26119318
15.

[Expression and regulation of the SOST gene].

Qin LJ, Ding DX, Cui LL, Huang QY.

Yi Chuan. 2013 Aug;35(8):939-47. Review. Chinese.

PMID:
23956082
16.

A review of osteocyte function and the emerging importance of sclerostin.

Compton JT, Lee FY.

J Bone Joint Surg Am. 2014 Oct 1;96(19):1659-68. doi: 10.2106/JBJS.M.01096. Review.

17.

Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions.

Weivoda MM, Oursler MJ.

Curr Osteoporos Rep. 2014 Mar;12(1):107-14. doi: 10.1007/s11914-014-0188-1. Review.

18.

Sclerostin: therapeutic horizons based upon its actions.

Costa AG, Bilezikian JP.

Curr Osteoporos Rep. 2012 Mar;10(1):64-72. doi: 10.1007/s11914-011-0089-5. Review.

PMID:
22234741
19.

Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.

Ke HZ, Richards WG, Li X, Ominsky MS.

Endocr Rev. 2012 Oct;33(5):747-83. doi: 10.1210/er.2011-1060. Epub 2012 Jun 20. Review.

PMID:
22723594
20.

Sclerostin and CKD-MBD.

Schiavi SC.

Curr Osteoporos Rep. 2015 Jun;13(3):159-65. doi: 10.1007/s11914-015-0263-2. Review.

PMID:
25691219

Supplemental Content

Support Center